Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
m (Jwarner moved page XmAb5574 (MOR00208) to MOR208) |
m |
||
| Line 5: | Line 5: | ||
===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ||
# Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. [https://www.ncbi.nlm.nih.gov/pubmed/25301708 PubMed] | # Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. [https://www.ncbi.nlm.nih.gov/pubmed/25301708 PubMed] | ||
| + | |||
| + | ===[[Diffuse large B-cell lymphoma]]=== | ||
| + | # '''Abstract:''' Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7514 link to abstract] | ||
| + | |||
| + | ==Also known as== | ||
| + | MOR00208, XmAb5574 | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 14: | Line 20: | ||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 13:54, 12 June 2017
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Preliminary data
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed
Diffuse large B-cell lymphoma
- Abstract: Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 link to abstract
Also known as
MOR00208, XmAb5574